zenocutuzumab
merus
['zenocutuzumab']
excellent talk by on her2 x her3 bispecific antibody zenocutuzumab for nrg1+cancers showing tumor reduction in 70% of pts, dor 9.1mo, and extremely favorable toxicity with most aes low grade and low rate of discontinuation due to toxicity. #asco22 
Bring your idea to life?? 
Creating successful IITs & optimizing drug development ?? 
Medica Scientia Innovation Research
 ????&????
https://t.co/yp3O5Lylqc